Search | Clinical Trials Finder

Conditions: AIDS
Interventions: Hyperbaric chamber; Device
Lead sponsor: Designed Altobaric Technology, Incorporated; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV-1 Infection
Interventions: Niacin, Aspirin, Fenofibrate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Doravirine, 2 NRTIs, DOR/3TC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 4 Weeks to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
Interventions: Lamivudine and adefovir, Adefovir alone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: COVID-19
Interventions: CovX; Device
Lead sponsor: Dascena; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression, Anxiety
Interventions: SER Familia; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV-1-infection
Interventions: Albuvirtide, 3BNC117, Baseline ART; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more

Conditions: HIV Infections
Interventions: Automated diary system; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: HIV Infection
Interventions: Blood draw; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Memphis, Tennessee

Conditions: Long COVID, Long Covid19
Interventions: Narrative Intervention for Long COVID-19 (NICO); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Septic Shock
Interventions: LB1148, Placebo; Drug
Lead sponsor: Leading BioSciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 23 more

Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions: 9vHPV Vaccine, mRNA-1273 Vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more

Conditions: HIV Infections
Interventions: Dextran sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions: Hematopoietic Stem Cell Transplant; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 4 Months to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more

Conditions: Healthcare-acquired Infection
Interventions: Copper-alloy surfaced patient care objects; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Nontuberculous Mycobacterial Lung Disease
Interventions: Bacteriophage Treatment; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19, SARS-CoV2 Infection
Interventions: Focal Mask; Device
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Human Immunodeficiency Virus
Interventions: Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention; Device · Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Brookline, Massachusetts

Conditions: Hepatitis C Virus
Interventions: Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more

Conditions: Dengue
Interventions: Recombinant live attenuated trivalent dengue vaccine, Placebo, rDEN2Δ30-7169 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Search by objective public record fields.

Effect of Repeated Exposures to Compressed Air on Patients With AIDS

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Lamivudine and Adefovir to Treat Chronic Hepatitis B

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Classification of COVID-19 Infection in Posteroanterior Chest X-rays

SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Microbicides Acceptability Among Sexually Active Young Women

Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

Narrative Intervention for Long COVID-19 (NICO)

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

Efficacy Of Copper To Reduce Acquisition Of Microbes and Healthcare-acquired Infections

Biomarkers of Phage Treatment Response in NTM and Other Infections

Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2